AtriCure (NASDAQ:ATRC) Reaches New 1-Year High – Here’s What Happened

Posted by Geri Gentry on Sep 23rd, 2026

AtriCure, Inc. (NASDAQ:ATRC – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $60.99 and last traded at $60.9210, with a volume of 76652 shares traded. The stock had previously closed at $58.83.

Wall Street Analysts Forecast Growth

ATRC has been the topic of a number of recent research reports. Zacks Research lowered AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. Needham & Company LLC boosted their price target on AtriCure from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, September 2nd. UBS Group decreased their price objective on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Piper Sandler lifted their target price on AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 27th. Finally, BTIG Research boosted their target price on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $53.30.

View Our Latest Analysis on AtriCure

AtriCure Stock Up 1.7%

The firm has a market cap of $3.04 billion, a price-to-earnings ratio of 284.38 and a beta of 1.26. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The stock has a 50-day moving average of $45.75 and a 200-day moving average of $34.86.

AtriCure (NASDAQ:ATRC – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The firm had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the prior year, the company posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Sell-side analysts predict that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at AtriCure

In other news, insider Karl S. Dahlquist sold 9,370 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $48.89, for a total value of $458,099.30. Following the completion of the transaction, the insider directly owned 87,319 shares in the company, valued at approximately $4,269,025.91. The trade was a 9.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Regina E. Groves sold 5,313 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $54.22, for a total transaction of $288,070.86. Following the sale, the director directly owned 34,546 shares of the company’s stock, valued at approximately $1,873,084.12. This trade represents a 13.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 70,349 shares of company stock valued at $3,046,757 over the last three months. 4.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Harbor Investment Advisory LLC bought a new stake in AtriCure during the second quarter worth $40,000. Allworth Financial LP bought a new position in shares of AtriCure in the 2nd quarter valued at $43,000. Integrated Wealth Concepts LLC bought a new position in shares of AtriCure in the 2nd quarter valued at $46,000. Fifth Third Bancorp acquired a new position in shares of AtriCure during the 1st quarter worth $51,000. Finally, Global Retirement Partners LLC bought a new stake in shares of AtriCure during the 4th quarter worth $73,000. 99.11% of the stock is owned by institutional investors.

About AtriCure

(Get Free Report)

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.